{"id":"W4367299362","doi":"10.57264/cer-2023-0009","title":"Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant","year":2023,"lang":"en","type":"letter","venue":"Journal of Comparative Effectiveness Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Palbociclib; Medicine; Fulvestrant; Oncology; Breast cancer; Quality of life (healthcare); Internal medicine; Cancer; Gynecology; Metastatic breast cancer; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005173713,0.0005401624,0.002116371,0.0008278685,0.001419621,0.001684886,0.001319819,0.01902465,0.005819571],"category_scores_gemma":[0.03917212,0.0005180489,0.001239628,0.001156365,0.001178183,0.001415422,0.0007319134,0.01515579,0.00344032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003938137,"about_ca_system_score_gemma":0.003603338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005810716,"about_ca_topic_score_gemma":0.008283153,"domain_scores_codex":[0.9965224,0.001639918,0.0006766086,0.0003293653,0.0005380498,0.0002936336],"domain_scores_gemma":[0.9777312,0.01655633,0.001359158,0.0004456344,0.002639008,0.001268623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001056825,0.0001050684,0.004901777,0.0002886364,0.0002027444,0.001317758,0.000115903,0.00009320839,0.0001847405,0.001323281,0.977621,0.01278908],"study_design_scores_gemma":[0.002958138,0.0008546181,0.02065395,0.001468234,0.001176755,0.00624715,0.001380358,0.001231247,0.0009008489,0.008344229,0.9545505,0.0002339749],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.001953524,0.001120191,0.00008088144,0.974655,0.02006082,0.00003351616,0.0007107199,0.00001923269,0.001365977],"genre_scores_gemma":[0.01100271,0.000959192,0.0003134397,0.9583652,0.02569372,0.00015472,0.00021278,0.00001922929,0.003279032],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.01902465,"threshold_uncertainty_score":0.02857333,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1251605424464233,"score_gpt":0.4609705745515502,"score_spread":0.3358100321051269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}